Newsletter: April 2022

WuXi Biologics Achieved Record Growth and Profitability in 2021 Banner Year for Commercial Manufacturing

WuXi Biologics is pleased to announce its audited annual results for the year ended December 31, 2021. Our CRDMO business model and a focus on innovation, quality, expertise, project execution and delivery timelines, along with our “Follow and Win the Molecule” strategies helped us capture opportunities, increase our market share, and achieve new revenue and profitability records in 2021

Read More

WuXi Biologics Wins CMO Leadership Awards in All Six Core Categories for Fifth Consecutive Year. Read More

WuXi Biologics Recognized as 2022 Top-Rated ESG Company by Sustainalytics. Read More

The Watershed Moment for ADCs has Arrived – More efficient CMC development is the last barrier

Ten years ago, antibody-drug conjugates (ADCs) were being talked about as the next big breakthrough in pharmaceuticals due to their highly targeted approach, especially in areas such as oncology… Download

7 Key Questions for Understanding the Benefits of Scale-out Biomanufacturing

Through a Question-and-Answer (Q&A) format, we review the inherent benefits of this bioproduction strategy as you scale throughout clinical trials and the significant cost advantages once in commercial production. Download

WuXi Biologics is committed to creating a workplace free of bias, stereotypes, and discrimination; a world that is diverse, equitable, and inclusive; a world where difference is valued and celebrated. We strive to create equal working opportunities, so that all employees believe their contributions are essential to the company’s success. For instance, over 50% of the company’s global workforce is female as is nearly 50% of the leadership team.

We celebrated International Women’s Day in March with our Women in STEM Employee Stories #BreakTheBias